The European Union has granted approval for Eli Lilly’s Kisunla, an Alzheimer’s treatment that initially faced a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) earlier this year. Following a re-evaluation in June, the drug has now secured its place in the EU market, marking a significant turnaround for Lilly and its Alzheimer’s portfolio.
This approval comes at a critical time as the demand for effective Alzheimer’s therapies continues to grow amidst rising patient populations in Europe. The re-evaluation process highlights the EU’s willingness to reconsider drug applications based on new data, which could set a precedent for future Alzheimer’s treatments seeking approval. For Lilly, this success not only enhances its reputation in the neurology space but also opens new avenues for market penetration and potential revenue growth.
In related news, Sanofi is expanding its insulin discount program, aiming to improve access to diabetes care. This initiative underscores the ongoing efforts within the pharmaceutical industry to address affordability and patient access, particularly in chronic disease management, which remains a focal point for regulatory and market strategies.
Open the full market picture for your next decision →
